<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938145</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-08063</org_study_id>
    <secondary_id>NCI-2012-00937</secondary_id>
    <nct_id>NCT00938145</nct_id>
  </id_info>
  <brief_title>3 Tesla MRI in Patients With Bladder Cancer</brief_title>
  <official_title>Imaging of Bladder Cancer Using Clinical 3 Tesla MRI and EX-VIVO Ultra-High-Field MRI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: New diagnostic procedures, such as 3 Tesla magnetic resonance imaging (MRI), may&#xD;
      help find bladder cancer and learn the extent of disease.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well 3 Tesla MRI works in finding cancer in&#xD;
      patients with bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate whether 3 Tesla MRI can accurately determine the primary tumor (T) stage and&#xD;
           pelvic lymph nodes (N) stage in patients with localized bladder cancer as compared to&#xD;
           histopathology staging.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine whether 3 Tesla MRI can determine if the primary bladder tumor is&#xD;
           responding to neoadjuvant chemotherapy at the mid-point of the planned treatment (after&#xD;
           2 courses).&#xD;
&#xD;
        -  To assess whether an ex-vivo ultra-high-field MRI (4.7-11.7 Tesla) tissue scan can more&#xD;
           accurately determine clinical stage of a primary bladder tumor and local extent of the&#xD;
           disease (i.e., involvement of contiguous organs and regional lymph nodes) as compared to&#xD;
           histopathology staging.&#xD;
&#xD;
      OUTLINE: Patients may receive neoadjuvant chemotherapy (typically four 21-day courses of&#xD;
      cisplatin-based therapy) followed by standard radical cystectomy and lymph node dissection.&#xD;
&#xD;
      Patients undergo a 3 Tesla MRI scan at baseline to stage the primary tumor, regional lymph&#xD;
      nodes, and to rule out distant sites of disease. The MRI includes diagnostic high-resolution&#xD;
      anatomical images (e.g., T1-weighted and T2-weighted images along axial or optimal&#xD;
      directions) and experimental images including functional MRI (e.g., dynamic contrast-enhanced&#xD;
      MRI, diffusion-weighted MRI, MR spectroscopy, and chemical exchange-dependent&#xD;
      saturation-transfer imaging). Patients also undergo a 3 Tesla MRI scan after 2 courses of&#xD;
      neoadjuvant chemotherapy and after completion of neoadjuvant chemotherapy. Patients not&#xD;
      receiving neoadjuvant chemotherapy undergo a 3 Tesla MRI scan 2-4 weeks before radical&#xD;
      cystectomy and lymph node dissection.&#xD;
&#xD;
      Specimens from the radical cystectomy and pelvic lymph node dissection are examined ex-vivo&#xD;
      by ultra-high-field MRI and the Micro-Imaging Specimen Study Form is completed. The specimens&#xD;
      are then examined by the pathology department as per standard routine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Agreement in tumor staging between pathology and 3 Tesla MRI</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Agreement in lymph node staging between pathology and 3 Tesla MRI</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>MRI+surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI+surgery+chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI/chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Specimen Ultra-High field MRI</intervention_name>
    <description>Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.</description>
    <arm_group_label>MRI+surgery</arm_group_label>
    <arm_group_label>MRI+surgery+chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).</description>
    <arm_group_label>MRI+surgery+chemotherapy</arm_group_label>
    <other_name>chemo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cystectomy and Lymphadenectomy</intervention_name>
    <description>The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.</description>
    <arm_group_label>MRI+surgery</arm_group_label>
    <arm_group_label>MRI+surgery+chemotherapy</arm_group_label>
    <other_name>surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known bladder cancer&#xD;
&#xD;
          -  Scheduled for radical cystectomy and lymph node dissection.&#xD;
&#xD;
          -  Able and willing to give valid written informed consent.&#xD;
&#xD;
          -  No contraindications to the MRI(magnetic resonance imaging).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not pregnant, planning to become pregnant during the study, or nursing.&#xD;
&#xD;
          -  No allergy to contrast agents.&#xD;
&#xD;
          -  Patient with significant renal insufficiency, i.e. an estimated glomerular filtration&#xD;
             rate(eGRF) less than 30 mL/min/1.73m2.&#xD;
&#xD;
          -  Any condition conflict based on the investigation's clinical judgment that would&#xD;
             prevent the patient from completion all trial assessments and visits.&#xD;
&#xD;
          -  Inability or unwillingness to cooperate with requirements of this trial.&#xD;
&#xD;
          -  Patients who exhibit noticeable anxiety and/or claustrophobia or who exhibit severe&#xD;
             vertigo when they are moved into the MR.&#xD;
&#xD;
          -  Patients with sickle cell anemia and other hemolytic anemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael V. Knopp, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ohio State University Comprehensive Cancer Center</last_name>
    <phone>1-800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Knopp, MD, PhD</last_name>
    <phone>614-293-9998</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Knopp, MD, PhD</last_name>
      <phone>614-293-9998</phone>
      <email>knopp.16@osu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 10, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Michael V. Knopp MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

